84. Sarcoidosis Clinical trials / Disease details


Clinical trials : 149 Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-002160-14-NL
(EUCTR)
22/11/201625/10/2016Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis.68Ga-DOTA-NOC PET/CT for the imaging of disease activity in neurologic and cardiac sarcoidosis. - SCAN-GO Trial Sarcoidosis.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: Gallium-68-DOTA-N-Octreotide
Product Code: Ga-68-DOTA-NOC
INN or Proposed INN: Ga-68-DOTA-NOC
Other descriptive name: DOTANOC
St. Antonius HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Netherlands
2EUCTR2013-005376-17-NL
(EUCTR)
20/06/201427/02/2014Sandostatin therapy in sarcoidosisSandostatin therapy in sarcoidosis - SST in SA Sarcoidosis
MedDRA version: 16.1;Level: HLGT;Classification code 10003816;Term: Autoimmune disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Sandostatin LAR
INN or Proposed INN: OCTREOTIDE
Other descriptive name: octreotide LAR / Sandostatin LAR (LAR=long acting release)
Erasmus Medical CenterNULLNot RecruitingFemale: yes
Male: yes
Netherlands